Becton Dickinson Research and Development Expenses 2010-2024 | BDX
Becton Dickinson annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Becton Dickinson research and development expenses for the quarter ending September 30, 2024 were $0.302B, a 7.47% increase year-over-year.
- Becton Dickinson research and development expenses for the twelve months ending September 30, 2024 were $1.190B, a 3.8% decline year-over-year.
- Becton Dickinson annual research and development expenses for 2024 were $1.19B, a 3.8% decline from 2023.
- Becton Dickinson annual research and development expenses for 2023 were $1.237B, a 1.51% decline from 2022.
- Becton Dickinson annual research and development expenses for 2022 were $1.256B, a 1.8% decline from 2021.
Becton Dickinson Annual Research and Development Expenses (Millions of US $) |
2024 |
$1,190 |
2023 |
$1,237 |
2022 |
$1,256 |
2021 |
$1,279 |
2020 |
$1,039 |
2019 |
$1,062 |
2018 |
$1,004 |
2017 |
$770 |
2016 |
$828 |
2015 |
$632 |
2014 |
$550 |
2013 |
$494 |
2012 |
$472 |
2011 |
$470 |
2010 |
$423 |
2009 |
$405 |
Becton Dickinson Quarterly Research and Development Expenses (Millions of US $) |
2024-09-30 |
$302 |
2024-06-30 |
$299 |
2024-03-31 |
$299 |
2023-12-31 |
$290 |
2023-09-30 |
$281 |
2023-06-30 |
$306 |
2023-03-31 |
$337 |
2022-12-31 |
$313 |
2022-09-30 |
$300 |
2022-06-30 |
$315 |
2022-03-31 |
$327 |
2021-12-31 |
$314 |
2021-09-30 |
$341 |
2021-06-30 |
$330 |
2021-03-31 |
$317 |
2020-12-31 |
$291 |
2020-09-30 |
$243 |
2020-06-30 |
$262 |
2020-03-31 |
$264 |
2019-12-31 |
$270 |
2019-09-30 |
$270 |
2019-06-30 |
$282 |
2019-03-31 |
$252 |
2018-12-31 |
$258 |
2018-09-30 |
$277 |
2018-06-30 |
$277 |
2018-03-31 |
$259 |
2017-12-31 |
$191 |
2017-09-30 |
$215 |
2017-06-30 |
$186 |
2017-03-31 |
$187 |
2016-12-31 |
$182 |
2016-09-30 |
$252 |
2016-06-30 |
$207 |
2016-03-31 |
$182 |
2015-12-31 |
$187 |
2015-09-30 |
$196 |
2015-06-30 |
$178 |
2015-03-31 |
$129 |
2014-12-31 |
$129 |
2014-09-30 |
$140 |
2014-06-30 |
$137 |
2014-03-31 |
$147 |
2013-12-31 |
$126 |
2013-09-30 |
$133 |
2013-06-30 |
$121 |
2013-03-31 |
$122 |
2012-12-31 |
$118 |
2012-09-30 |
$128 |
2012-06-30 |
$115 |
2012-03-31 |
$117 |
2011-12-31 |
$112 |
2011-09-30 |
$121 |
2011-06-30 |
$114 |
2011-03-31 |
$119 |
2010-12-31 |
$116 |
2010-09-30 |
$115 |
2010-06-30 |
$108 |
2010-03-31 |
$100 |
2009-12-31 |
$99 |
2009-09-30 |
$110 |
2009-06-30 |
$98 |
2009-03-31 |
$99 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical & Dental Supplies |
$64.352B |
$20.178B |
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|